Dr Singh hails from Malaysia where he studied medicine in the Melaka Manipal Medical College. He was the top achiever in his class, winning multiple awards for various subjects including the prestigious TMA Pai Gold Medal for Overall Best Student in both the pre-clinical and clinical phases of his MBBS degree program. His interest in research began while he was a student, earning him accolades from various national conferences.
He continued to develop his capabilities in conducting clinical research while training as a junior doctor in Kuala Lumpur General Hospital; Malaysia’s apex referral centre. During this period, he presented his research findings in numerous national and international cardiology conferences, winning multiple awards for his work. During the same period, he also gained membership to the Royal Colleges of Physicians (UK) and served as Speciality Registrar in Internal Medicine.
He is currently pursuing his MD, studying the effect of SGLT-2 inhibitors on the cardiovascular system. He is also actively involved in a number of phase III and phase IV commercial trials studying heart failure therapeutics.
Principal Investigator - Research into the Effect Of SGLT2 inhibition on left ventricular Remodeling in patients with heart failure and diabetes Mellitus (REFORM Trial) .
Co-investigator in a number of investigator led studies and trials.
Singh JS, Lang CC. Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. Vascular Health and Risk Management 2015:11 1–13
Vun Heng Chong, Jagdeep Singh, Helen Parry, Jocelyn Saunders, Farhad Chowdhury, Donna M Mancini, Chim C Lang. Management of non-cardiac comorbidities in chronic heart failure. Clinical Therapeutics (accepted for publication)